Clinical Expression, Prognosis and Immune Infiltration of SUV39H1 in Diffuse Large B-cell Lymphoma

Abstract Epigenetic regulation plays a crucial part in the oncogenesis and treatment of diffuse large B-cell lymphoma (DLBCL). The H3K9me3-specific histone methyltransferase SUV39H1 is a significantly epigenetic gene that promotes the progression of a variety of malignancies. However, the roles of SUV39H1 in DLBCL remain unclear. By retrieving Oncomine, GEPIA, CCLE, UALCAN, and TCGA databases, we observed that the expression of SUV39H1 was higher in DLBCL tissues than in normal and other cancer tissues. Combined with immunohistochemical validation assay, we analysed clinical characteristics of DLBCL patients. The results showed that high expression of SUV39H1 was closely associated with age over 50 years old (P=0.014) and low albumin level (P=0.015). In the prognostic analyses, DLBCL patients in GEPIA database showed that the high SUV39H1 expression group had a lower disease-free survival (DFS) rate than the low SUV39H1 expression group (P=0.035). Finally, we discovered that expressions of CD86+ and CD163+ macrophages have high correlations with SUV39H1+ in DLBCL tissues(with P=0.037 and P=0.045,respectively). SUV39H1-associated macrophages may downregulate T lymphocyte subsets, especially Treg cells in DLBCL(P=0.003). In summary, SUV39H1 might be not only a potential target for the epigenetic therapy and immunotherapy of DLBCL, but also a clinical indicator for doctors to evaluate the trend of disease development.